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Treatment guidelinesAbstract Background: Patients with gastrointestinal stromal tumour (GIST) are often
followed up after surgery with longitudinally repeated imaging examinations to detect recur-
rence early. Studies on follow-up of GIST patients are few, the optimal follow-up methods are
unknown and the recommendations for follow-up vary in guidelines.
Methods: We reviewed the current evidence for follow-up of patients treated with surgery
alone and of patients who were treated with adjuvant or neoadjuvant imatinib.
Results: Imaging of the abdomen and the pelvis with computerised tomography (CT) or mag-
netic resonance imaging (MRI) usually sufﬁces, since metastases are uncommon at other sites.
The frequency of imaging may be adjusted with the risk of recurrence with time.
Very low risk GISTs are very frequently cured with surgery and usually require no regular
follow-up after complete surgery, and annual CT of the abdomen and the pelvis for 5 years
sufﬁces for most patients with a low to intermediate risk for recurrence. Most high-risk
patients are treated with imatinib for at least 3 years after surgery. CT or MRI may be carried
out 6-monthly during adjuvant imatinib, 3 to 4-monthly during the 2 years that followkatu 4,
ishida),
1612 H. Joensuu et al. / European Journal of Cancer 51 (2015) 1611–1617discontinuation of imatinib when the risk of recurrence is high, and then at 6–12 month inter-
vals to complete 10 years of follow-up. Recurrence after the ﬁrst 10 years of follow-up is infre-
quent.
Conclusions: The follow-up schedules are best tailored with the risk of recurrence. The risk of
recurrence should be estimated with the prognostic tools that consider the most relevant
prognostic factors.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CCBY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Gastrointestinal stromal tumour (GIST) is by some
estimates the most common single type of sarcoma [1].
GISTs arise at any site of the gastrointestinal tract, most
frequently in the stomach [2]. Oesophageal GISTs are
rare (<1% of all GISTs), and therefore almost all
GISTs arise from a site located below the diaphragm
[2]. Most GISTs (80–85%) are localised when detected
[2,3], but they frequently give rise to metastases.
Metastases usually arise in the liver and within the
abdominal cavity, whereas pulmonary, bone, lymph
node and brain metastases are uncommon. Mutations
in KIT and PDGFRA are considered the driving molec-
ular aberrations, but in 10–15% of GISTs both KIT and
PDGFRA are wild type in gene sequencing (‘wild type
GISTs’). Mutations are often found in other genes than
KIT and PDGFRA in these GISTs [4].
The standard treatment of localised GIST is its
macroscopically complete removal whenever feasible.
Preoperative imatinib may be given to shrink a large
GIST to improve its operability and to spare normal tis-
sues, in particular when GIST is located at a site where
extensive resections of normal tissues would otherwise
be required. Patients with a high risk for recurrence
are treated after surgery with adjuvant imatinib.
Imatinib reduces the risk of recurrence [5–7] and may
improve survival [6] provided that GIST harbours an
imatinib-sensitive mutation in KIT or PDGFRA. The
standard duration of adjuvant imatinib is currently
3 years [6].
Approximately 60% of patients with operable GIST
survive 10 or more years after surgery [8], and most
GIST patients are subjected to clinical follow-up after
surgery. Yet, the optimal procedures of follow-up are
poorly deﬁned, as prospective studies have not been
conducted to investigate diﬀerent follow-up schedules
and methods, likely due to the rarity of GIST and
the cost of such studies. In this article we review the
key evidence concerning planning of follow-up strate-
gies for GIST patients who have undergone surgery
for GIST. To our knowledge, articles focusing on
the follow-up strategies and their rationale in a patient
population with operable GIST are not available in
the literature.2. Objectives of follow-up
An important question is whether patients who have
undergone macroscopically complete surgery beneﬁt
from regular follow-up, or might repeat imaging exam-
inations even be harmful due to the radiation hazard
and other hazards involved, such as those associated
with contrast agent administration. In the absence of
randomised trials the answer remains unknown, but
the trade-oﬀ between the beneﬁts and the harms likely
depends on the risk of recurrence, the frequency and
the type of imaging examinations performed, and the
potential beneﬁts associated with early detection and
treatment of recurrence.
GIST recurrence may be associated with abdominal
pain, sudden or insidious bleeding leading to anaemia
and fatigue, and changes in the bowel function. In the
authors’ experience, most recurrences detected during
a scheduled follow-up programme consisting of longitu-
dinally repeated computerised tomography (CT) exami-
nations are either asymptomatic or minimally
symptomatic, suggesting that follow-up schedules may
spare the patient from symptoms related to bulky
GIST metastases.
The most important consideration that favours regu-
lar follow-up is the potential for early detection of recur-
rence at a time when the tumour bulk is still small.
Emergence of secondary KIT mutations leading to
acquired drug resistance is very frequent in the treat-
ment of advanced GIST, and drug resistance is the most
important cause for treatment failure in the advanced
disease setting [9]. Patients with a large tumour bulk at
the time of imatinib initiation for advanced GIST have
the shortest time to imatinib failure [10], suggesting that
the risk of secondary mutations that confer drug resis-
tance is a function of tumour mass, although the lead
time bias is a confounding factor. Therefore, detection
of recurrence early might prolong the time to drug resis-
tance, which in turn might lead to achieving longer sur-
vival. However, there are few research data available to
support this hypothesis.
3. Evaluation of the risk of recurrence after surgery
GIST patients have a widely variable risk for recur-
rence after surgery ranging from virtually no risk in
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limetres in diameter to close to 100% in patients with
ruptured GIST or large non-gastric GISTs with a high
mitotic rate [8]. As the main purpose of follow-up is to
detect recurrence early, the eﬃcacy of follow-up sched-
ules is likely the higher the better they are adjusted to
the risk of GIST recurrence over time.
The most important prognostic factor for recurrence
is tumour proliferation rate, which is often assessed by
counting of the number of mitotic ﬁgures per 50 high
power ﬁelds (HPFs) of the microscope, or by providing
the number of mitotic ﬁgures per 1 mm2 of tumour
[8,11–13]. Although mitosis counting is subject to con-
founders, such as lack of reliable identiﬁcation of
mitoses, variations in the size of the ﬁeld-of-view of
the microscope, and the quality of tissue ﬁxation, high
mitotic counts are consistently associated with poor out-
come in diﬀerent studies [14]. Other factors that are fre-
quently independently associated with a high risk of
recurrence include non-gastric location of GIST, large
size and tumour rupture [14,15].
Outcome of GIST patients is usually estimated with
one of the prognosis stratiﬁcation tools. Of these, the
Armed Forces Institute of Pathology (AFIP) risk strat-
iﬁcation [16], the modiﬁed National Institutes of Health
scheme [2,14], and the prognostic heat maps [8] may be
the most frequently used methods. All of these schemes
consider tumour mitotic count, site and size and the
modiﬁed National Institutes of Health (NIH) scheme
and the prognostic heat maps consider also tumour rup-
ture. All three tools are validated [8].
Whether GIST mutational data should be included in
risk stratiﬁcation is controversial. KIT exon 9 mutation
or the mutations involving KIT exon 11 codons 557
and/or 558 are associated with a high risk of recurrence,
and, on the other hand, PDGFRAmutation D842V with
favourable outcome [17–21]. However, patients with an
identical KIT or PDGFRA mutation may have widely
diﬀerent outcomes depending on the tumour mitotic rate
suggesting that further genetic aberrations may inﬂuence
the risk of recurrence more than the KIT or PDGFRA
mutation [21]. Multigene panels based on gene expres-
sion or tumour DNA aberrations are promising prog-
nostic tools [22]. In general, the standard prognostic
factors are more important in the estimation of progno-
sis than the KIT or PDGFRA mutation type.
In sum, risk stratiﬁcation tools should be consulted
when the risk of recurrence after surgery is being evalu-
ated. These schemes are better prognosis estimators than
their single components, such as tumour size. Tools
where the mitotic count and size are treated as continu-
ous variables [8] are recommended when tumour mitotic
count or size is equal or close to the cut-oﬀ value of a
categorised prognostication tool, e.g. 5 mitotic
counts/50 HPFs or 5.0 cm, since the estimated risk for
recurrence often diﬀers substantially between GISTsthat have mitotic count or size just above or below the
cut-oﬀ value [14,16].4. Estimation of the risk of recurrence after adjuvant
imatinib
The most reliable data for estimation of the risk of
recurrence in a patient population treated with adjuvant
imatinib comes from the analyses of the randomised tri-
als that evaluated adjuvant imatinib in the treatment of
operable GIST. The most important factors that predict
recurrence after surgery and adjuvant therapy turned
out to be largely the same factors that predict GIST
recurrence after surgery only.
In an analysis of the SSGXVIII/AIO trial data [6] the
factors that predicted GIST recurrence independently in
a multivariable analysis were a high tumour mitotic
count, a non-gastric site of origin, large size, presence
of tumour rupture and administration of adjuvant ima-
tinib for 12 months compared to 36 months [23]. A risk
score constructed with these factors had a concordance
index with GIST recurrence of 78.9% [23]. The score
was validated in the ACOSOG Z9001 trial patient pop-
ulation treated with adjuvant imatinib for 12 months
[23]. Similarly, in the ACOSOG Z9001 trial imatinib
arm tumour size, location and mitotic rate indepen-
dently predicted GIST recurrence in a multivariable
model [24].
Adjuvant imatinib inﬂuences greatly the pattern of
GIST recurrence in time. While the risk of recurrence
after surgery is the highest during the 2 years that follow
surgery and decreases gradually thereafter, the patients
treated with adjuvant imatinib are at a relatively small
risk at the time when they are on imatinib, but have a
substantially increased risk during the few years that fol-
low discontinuation of imatinib [6]. These data imply
that imatinib often delays the risk of recurrence in
patients who have undergone surgery for high-risk
GIST.
The diﬀerent patterns of GIST recurrence in time in
patient populations treated with surgery only and those
treated with surgery plus adjuvant imatinib argue for
distinct follow-up schedules for these two populations
to achieve early detection of recurrence while minimising
radiation hazards. High-risk patients treated with adju-
vant imatinib likely beneﬁt from schedules where imag-
ing is relatively sparse during adjuvant imatinib, but
more frequent during the few years that follow imatinib
discontinuation when the risk of recurrence is particu-
larly high. An exception to this rule may be the patients
who have high tumour mitotic counts (e.g. gastric
GISTs with >50 mitoses or non-gastric GISTs with
>20 mitoses/50 HPFs), since such tumours frequently
recur during adjuvant imatinib [23]. To achieve the most
favourable trade-oﬀs between early detection of recur-
rence and keeping the cumulative radiation dose from
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follow-up CT scans in time during and after adjuvant
imatinib treatment was constructed [25].5. Duration of follow-up
The most reliable information about the long-term
outcome of GIST patients treated with surgery alone
may be obtained from the population-based series with
long follow-up available, although modern imaging
and diagnostic improvements may have shortened the
time to detection of recurrence. These data show that
approximately 70% of all recurrences occur within the
ﬁrst 5 years, 90% within 10 years and about 95% within
15 years from surgery [8], while recurrence after 20 years
of follow-up is rare [8,12,13]. Metastases from very low
and low-risk GISTs are only rarely detected after the
ﬁrst 10 years of follow-up, although their generally low
mitotic rate might suggest a long natural disease history
[8].
These ﬁndings suggest that the beneﬁts of imaging
decreases with time, and may be of only limited value
after the ﬁrst 10 years of follow-up after surgery. The
rare patients with syndromic GIST, including patients
with SDH deﬁcient GIST, may be exceptions, since
these GISTs may progress very slowly and may be asso-
ciated with other tumours, such as paragangliomas and
adrenal adenomas, arguing for a more extended
follow-up of such patients [2].6. Follow-up methods
Nearly all GIST recurrences manifest as metastases in
the abdominal cavity [26]. Metastasis outside of the
abdomen without detectable progression within the
abdominal cavity is so infrequent that presence of
another malignancy should be suspected in such cases,
and a tissue biopsy is recommended. For most GIST
patients, longitudinal imaging of the abdomen and pel-
vis suﬃces for follow-up [27].
GIST patients are usually followed up with CT, per-
formed with a contrast agent when feasible. Magnetic
resonance imaging (MRI) is an alternative to CT espe-
cially in young patients to minimise radiation exposure,
but MRI is more costly and access to MRI is generally
more limited than to CT. The average eﬀective radiation
dose associated with one abdominal CT is approxi-
mately 8 mSv, which corresponds to the dose received
from the natural background radiation over approxi-
mately 3 years [28]. Therefore, the radiation hazards
from abdominal/pelvic CT scans appear justiﬁable com-
pared with the life-threatening nature of bulky GIST
recurrence.
Ultrasound examination of the abdomen is usually
not optimal, since ultrasound waves do not traverse air,
andmetastasesmay remain undetectable. Young patientswith wild-type GIST may be an exception due to the high
frequency of liver metastases in this patient population,
to avoid ionising radiation, and as eﬀective adjuvant ther-
apy is unavailable for this patient population. However,
paediatric, paediatric-type and syndromic GISTs not
infrequently give rise to metastases in intra-abdominal
lymph nodes [29,30] and other intra-abdominal sites that
are not readily detected with ultrasound.
Other imaging examinations, such as
positron-emission tomography (PET), PET-CT,
Doppler ultrasound, or isotope scans have limited value
in the follow-up, but they may provide further informa-
tion in patients who have a lesion of an undeﬁned nature
in CT or MRI. PET is useful for assessing the metabolic
activity of GIST lesions, and may be helpful when sur-
gery is considered.
Most recurrences are detected at imaging, but not all,
and, therefore, taking patient history and performing
physical examination periodically are recommended
especially in the patient population with high-risk
GIST. There is no evidence to recommend any blood
test for follow-up, although blood haemoglobin and cell
counts, and serum liver transaminase and alkaline phos-
phatase concentrations are often measured.7. Follow-up procedures in guidelines
Clinical practice guidelines provide some advice
about GIST patient follow-up, but e.g. the National
Comprehensive Cancer Network (NCCN) of the U.S.
and the European Society for Clinical Oncology
(ESMO) guidelines diﬀer [31,32], and are mostly based
on expert consensus opinions.
The NCCN guidelines recommend performing
abdominal/pelvic CT with contrast every 3–6 months
for 3–5 years after complete surgery for GIST, and then
annually with the exception of patients with GIST
<2 cm in diameter, who may have less frequent surveil-
lance. The overall duration of surveillance is not deﬁned,
and might thus be interpreted to continue for the rest of
the patient’s life. The guidelines recommend discussing
patient history and performing physical examination at
3–6 month intervals. The follow-up recommendations
are similar for patients treated with surgery only and
for those treated with preoperative and/or adjuvant
imatinib [31].
The ESMO guidelines acknowledge that the optimal
follow-up policy is unknown [32]. Risk assessment based
on tumour mitotic count, size and site may be used for
selection of the follow-up policy. The guidelines state
that as an example, high-risk patients could be followed
up with abdominal CT or MRI every 3–6 months for
3 years during adjuvant therapy, at 3-month intervals
after stopping adjuvant therapy, and annually for fur-
ther 5 years. Patients with low-risk GIST may be fol-
lowed up with abdominal CT or MRI every 6–
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ommend follow-up for very low-risk tumours.8. Authors’ recommendations
The authors consider follow-up potentially valuable
for selected patients to achieve early detection of recur-
rence, despite the optimal method is unknown.
The follow-up strategy should be adjusted to the risk
of GIST recurrence. The risk estimation tools, such as
the modiﬁed NIH scheme, the AFIP scheme and the
prognostic heat maps are likely more accurate than
GIST size in the estimation of the risk of recurrence,
and, therefore, the follow-up strategy should not be
based on size alone. Adjuvant imatinib decreases the
risk of recurrence and changes the pattern of recurrence
in time, and, therefore, adjuvant imatinib administra-
tion and its duration need to be considered in the plan-
ning of follow-up. The mainstay of follow-up is
abdominal/pelvic imaging, which is usually done with
CT.
Examples of recommended follow-up schemes after
surgery for localised GIST are shown in Table 1. The
patients with the lowest risk are unlikely to beneﬁt from
longitudinal imaging, since they are usually cured by
surgery.
For the purposes of patient follow-up, the intermedi-
ate risk group may be deﬁned as in Table 1. Most inter-
mediate risk patients are cured by surgery with most
recurrences detected within the 5 years that follow sur-
gery. The beneﬁt of regular monitoring with CT or
MRI may be small in this patient population.
High-risk patients are candidates for adjuvant ima-
tinib with the exception of patients whose GISTTable 1
Follow-up of gastrointestinal stromal tumour (GIST) patients treated with
Risk group Recurrence risk evaluation method
Modiﬁed National Institutes of
Health (NIH) scheme [14]
Armed Forces
Institute of
Pathology (AFIP)
scheme [16]
Very low risk 62.0 cm, 65 mitoses/50 high power
ﬁelds (HPFs), any tumour site
Group 1
Low risk 2.1–5.0 cm, 65 mitoses/50 HPFs,
any tumour site
Group 2
Intermediate
risk
62.0 cm, 6–10 mitoses/50 HPFs,
gastric tumour OR 5.1–10.0 cm, 65
mitoses/50 HPFs, gastric tumour
Group 3a
High riska The rest of the patients; any patient
with tumour rupture
Groups 3b, 4, 5, 6
6b
a Patients with a high estimated risk for GIST recurrence should be treate
as shown in Table 2. The recommendations shown in Table 1 apply onl
imatinib resistance (notably PDGFRA exon 18 mutation D842V) or is wildharbours a mutation that confers imatinib resistance
(notably PDGFRA mutation at the codon D842), or is
wild-type for KIT and PDGFRA. Since the risk of recur-
rence is relatively low during adjuvant imatinib but high
after stopping imatinib, we suggest shorter imaging
intervals of about 3–4 months during the time period
of approximately 2 years following discontinuation of
imatinib (Table 2). Patients with GIST that has a very
high mitotic count [23] and those with KIT exon 9 muta-
tion when treated with imatinib 400 mg/day have a
higher risk for recurrence during adjuvant therapy,
and we recommend that such patients have somewhat
more frequent abdominal imaging despite being on
imatinib.
Response to neoadjuvant imatinib requires careful
monitoring. Tumour mutation analysis is recommended
to identify KIT exon 9 mutations and
imatinib-insensitive mutations. CT or MRI is recom-
mended immediately before starting neoadjuvant treat-
ment and approximately 4 weeks after the date of
treatment initiation to assess response early.
Comparison of tumour density (Hounsﬁeld units)
between the baseline and follow-up CT scans is recom-
mended, since decreased density is usually compatible
with response despite lacking shrinking in tumour size.
PET or CT-PET may be more sensitive than CT alone
in the response assessment. A decrease in the tumour ﬂu-
orodeoxyglucose (FDG) uptake often occurs sooner
(frequently within a few days) than tumour volume
change [33]. Imatinib is often administered for approxi-
mately 4–6 months prior to surgery provided that the
tumour responds, but the optimal durations are unde-
ﬁned. Imaging of the abdomen should be performed
during this time period at approximately 2-monthsurgery alone.
Follow-up recommendation
Prognostic
heat maps
[8]
0–10% Likely cured by surgery. No regular follow-up
0–10% No follow-up; OR abdominal/pelvic
computerised tomography (CT)/ magnetic
resonance imaging (MRI) annually for
approximately 5 years
10–20% Abdominal/pelvic CT/MRI annually for
approximately 5 years, the ﬁrst scan
approximately 6–8 months after surgery
a, 30–100% Abdominal CT/MRI 6-monthly for the ﬁrst
5 years, then annually for the next 5 years (the
total duration of follow-up is 10 years after
surgery)
d with adjuvant imatinib, and they are recommended to be followed up
y to high-risk patients whose GIST contains a mutation that confers
-type for KIT and PDGFRA.
Table 2
Follow-up of gastrointestinal stromal tumour (GIST) patients treated with surgery and adjuvant imatinib.
Risk group During adjuvant imatinib (currently
administered for 3 years)
The 2 years that follow
discontinuation of adjuvant
imatiniba
The rest of the follow-up period (up to
approximately 10 years from imatinib
initiation)
High risk (30%
to 100% risk)
Abdominal/pelvic computerised tomography
(CT)/ magnetic resonance imaging (MRI) 6
monthlyb
Abdominal/pelvic CT/MRI at
3–4 month intervals
Abdominal/pelvic CT at 6–12 month
intervals
a Patients who discontinue adjuvant imatinib early due to intolerance are followed up as other patients who discontinue adjuvant imatinib.
b Patients with a high tumour mitotic count may require more frequent imaging while being treated with adjuvant imatinib (see text).
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ever feasible. Patients treated with neoadjuvant imatinib
usually have high-risk GIST and are treated with adju-
vant imatinib after surgery, and may then be followed
up as other high-risk patients (Table 2).
The clinical value of physical examination and blood
tests appears limited. GIST recurrence is only rarely
detected at physical examination when abdominal CT
is normal, and no blood test has been found helpful in
early detection of recurrence. Yet, periodic patient his-
tory and physical examination are likely worthwhile to
carry out in the patient population with high-risk
GIST. Most locoregional recurrences are detected early
by CT, but gastroscopy or sigmoidoscopy performed a
few months after surgery and potentially serially at later
times may be indicated when only an R1 resection of
oesophageal, gastric or rectal GIST was achieved at sur-
gery, and in syndromic GIST to detect second primary
GISTs or multifocal GIST.Conﬂict of interest statement
H. Joensuu has received an honorarium from
Blueprint Medicines, Ariad Pharmaceuticals and Orion
Corporation; J. Martin-Broto has received an honorar-
ium from Bayer, GlaxoSmithKline, PharmaMar,
Amgen and Novartis; T. Nishida has received research
grants from Novartis and Bayer, and an honorarium
from Pﬁzer, Bayer, and Novartis; P. Reichardt has
received an honorarium from Novartis, Pﬁzer, and
Bayer, and attended advisory boards of Novartis,
Pﬁzer, Bayer, and Ariad; P. Scho¨ﬀski has received
research support and honoraria from Novartis and
Bayer; R.G. Maki has received research support from
Sarcoma Alliance for Research through Collaboration,
honoraria from Bayer and GlaxoSmithKline, and con-
sulting fees from Bayer.Acknowledgements
Financial support: Academy of Finland, Cancer
Society of Finland, Sigrid Juselius Foundation, Jane
and Aatos Erkko Foundation. No writing assistance
was involved.References
[1] Ducimetie`re F, Lurkin A, Ranche`re-Vince D, Decouvelaere AV,
Pe´och M, Istier L, et al. Incidence of sarcoma histotypes and
molecular subtypes in a prospective epidemiological study with
central pathology review and molecular testing. PLoS One
2011;6(8):e20294.
[2] Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal
tumour. Lancet 2013;382(9896):973–83.
[3] Woodall CE, Brock GN, Fan J, et al. An evaluation of 2537
gastrointestinal stromal tumors for a proposed clinical staging
system. Arch Surg 2009;144(7):670–8.
[4] Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal
tumours: origin and molecular oncology. Nat Rev Cancer
2011;11(12):865–78.
[5] DeMatteo RP, Ballman KV, Antonescu CR, et al. Adjuvant
imatinib mesylate after resection of localised, primary gastroin-
testinal stromal tumour: a randomised, double-blind, placebo-
controlled trial. Lancet 2009;373(9669):1097–104.
[6] Joensuu H, Eriksson M, Sundby Hall K, et al. Twelve vs. 36
months of adjuvant imatinib as treatment of operable GIST with
a high risk of recurrence. Final results of a randomized trial
(SSGXVIII/AIO). JAMA 2012;307(12):1265–72.
[7] Casali PG, Le Cesne A, Poveda AV, Kotasek D, Rutkowski P,
Hohenberger P, et al. Imatinib failure-free survival (IFS) in
patients with localized gastrointestinal stromal tumors (GIST)
treated with adjuvant imatinib (IM): The EORTC/AGITG/FSG/
GEIS/ISG randomized controlled Phase III trial. J Clin Oncol
2013;31(15s):632s [abstract].
[8] Joensuu H, Vehtari A, Riihima¨ki J, et al. Risk of recurrence of
gastrointestinal stromal tumour after surgery: an analysis of
pooled population-based cohorts. Lancet Oncol 2012;13:265–74.
[9] Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations
and imatinib response in patients with metastatic gastrointestinal
stromal tumor. J Clin Oncol 2003;21(23):4342–9.
[10] Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M,
Benjamin RS, et al. Phase III randomized, intergroup trial
assessing imatinib mesylate at two dose levels in patients with
unresectable or metastatic gastrointestinal stromal tumors
expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol
2008;26(4):626–32.
[11] DeMatteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size,
and location independently predict recurrence after resection of
primary gastrointestinal stromal tumor (GIST). Cancer
2008;112(3):608–15.
[12] Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal
tumors of the stomach. A clinicopathologic, immunohistochem-
ical, and molecular genetic study of 1765 cases with long-term
follow-up. Am J Surg Pathol 2005;29(1):52–68.
[13] Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal
stromal tumors of the jejunum and ileum. A clinopathologic,
immunohistochemical, and molecular genetic study of 906 cases
before imatinib with long-term-follow-up. Am J Surg Pathol
2006;30(4):477–89.
H. Joensuu et al. / European Journal of Cancer 51 (2015) 1611–1617 1617[14] Joensuu H. Risk stratiﬁcation of patients diagnosed with
gastrointestinal stromal tumor. Hum Pathol 2008;39(10):1411–9.
[15] Hohenberger P, Oladeji O, Licht T, Dimitrakopoulou-Strauss A,
Jakob J, Pink D, et al. Neoadjuvant imatinib and organ
preservation in locally advanced gastrointestinal stromal tumors
(GIST). J Clin Oncol 2009;27(15S):548 [Suppl.; abstract].
[16] Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathol-
ogy and prognosis at diﬀerent sites. Semin Diagn Pathol
2006;23(2):70–83.
[17] Ku¨nstlinger H, Huss S, Merkelbach-Bruse S, et al.
Gastrointestinal stromal tumors with KIT exon 9 mutations:
Update on genotype-phenotype correlation and validation of a
high-resolution melting assay for mutational testing. Am J Surg
Pathol 2013;37(11):1648–59.
[18] Wardelmann E, Losen I, Hans V, Neidt I, Speidel N, Bierhoﬀ E,
et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane
domain of the c-kit protooncogene is associated with metastatic
behavior of gastrointestinal stromal tumors. Int J Cancer
2003;106(6):887–95.
[19] Martin-Broto J, Gutierrez A, Garcia-del-Muro X, Lopez-
Guerrero JA, Martinez-Trufero J, de Sande LM, et al.
Prognostic time dependence of deletions aﬀecting codons 557
and/or 558 of KIT gene for relapse-free survival (RFS) in
localized GIST: a Spanish Group for Sarcoma Research (GEIS)
Study. Ann Oncol 2010;21(7):1552–7.
[20] Wozniak A, Rutkowski P, Piskorz A, Ciwoniuk M, Osuch C,
Bylina E, et al. Prognostic value of KIT/PDGFRA mutations in
gastrointestinal stromal tumours (GIST): Polish Clinical Registry
experience. Ann Oncol 2012;23(2):353–60.
[21] Joensuu H, Rutkowski P, Nishida T, Steigen SE, Brabec P, Plank
L, et al. KIT and PDGFRA mutations and the risk of
gastrointestinal stromal tumor recurrence. J Clin Oncol
2015;33(6):634–42.
[22] Lagarde P, Pe´rot G, Kauﬀmann A, Brularf C, Dapremont V,
Hostein I, et al. Mitotic checkpoints and chromosome instability
are strong predictors of clinical outcome in gastrointestinal
stromal tumors. Clin Cancer Res 2012;18(3):826–38.
[23] Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D,
Schu¨tte J, et al. Risk factors for gastrointestinal stromal tumorrecurrence in patients treated with adjuvant imatinib. Cancer
2014;120(15):2325–33.
[24] Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki
RG, Pisters PWT, et al. Pathologic and molecular features
correlate with long-term outcome after adjuvant therapy of
resected primary GI stromal tumor: the ACOSOG Z9001 trial. J
Clin Oncol 2014;32(15):1563–70.
[25] Joensuu H, Reichardt P, Eriksson M, Sundby Hall K, Vehtari A.
Gastrointestinal stromal tumor: a method for optimizing the
timing of CT scans in the follow-up of cancer patients. Radiology
2014;271(1):96–103.
[26] DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruﬀ JM,
Brennan MF. Two hundred gastrointestinal stromal tumors:
recurrence patterns and prognostic factors for survival. Ann Surg
2000;231(1):51–8.
[27] Rutkowski P, Lugowska I. Follow-up of soft tissue sarcomas.
Memo 2014;7(2):92–6.
[28] Davies HE, Wathen CG, Gleeson FV. The risks of radiation
exposure related to diagnostic imaging and how to minimise
them. BMJ 2011;342:d947.
[29] Agaimy A, Wu¨nsch PH. Lymph node metastasis in gastrointesti-
nal stromal tumours (GIST) occurs preferentially in young
patients < or = 40 years: an overview based on our case material
and the literature. Langenbecks Arch Surg 2009;394(2):375–81.
[30] Rege TA, Wagner AJ, Corless CL, Heinrich MC, Hornick JL.
“Pediatric-type” gastrointestinal stromal tumors in adults: dis-
tinctive histology predicts genotype and clinical behavior. Am J
Surg Pathol 2011;35(4):495–504.
[31] National Comprehensive Cancer Network guidelines Version 2.
Center <http://www.nccn.org/professionals/physician_gls/pdf/
sarcoma.pdf>; 2014 (visited on Jan 29, 2015).
[32] ESMO/European Sarcoma Network Working Group.
Gastrointestinal stromal tumors: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol
2014;25(Suppl. 3):iii21–6.
[33] Choi H. Response evaluation of gastrointestinal stromal tumors.
Oncologist 2008;13(Suppl 2):4–7.
